NAD (+) biosynthesis, aging, and disease

Nicotinamide adenine dinucleotide (NAD (+)) biosynthesis and its regulation have recently been attracting markedly increasing interest. Aging is marked by a systemic decrease in NAD (+) across multiple tissues. The dysfunction of NAD (+) biosynthesis plays a critical role in the pathophysiologies of multiple diseases, including age-associated metabolic disorders, neurodegenerative diseases, and mental disorders. As downstream effectors, NAD (+)-dependent enzymes, such as sirtuins, are involved in the progression of such disorders. These recent studies implicate NAD (+) biosynthesis as a potential target for preventing and treating age-associated diseases. Indeed, new studies have demonstrated the therapeutic potential of supplementing NAD (+) intermediates, such as nicotinamide mononucleotide and nicotinamide riboside, providing a proof of concept for the development of an effective anti-aging intervention.